Search results
Author(s):
Rafael de la Espriella
,
Gonzalo Núñez-Marín
,
Pau Codina
,
et al
Added:
5 months ago
Author(s):
Estefania Oliveros
,
Yevgeniy Brailovsky
,
Paul Scully
,
et al
Added:
3 years ago
This review focuses on the implications of coronavirus disease 2019 (COVID-19) in the heart failure (HF) population. First of all, we will describe the cardiovascular implications of COVID-19 and the new practices surrounding the use of telehealth to follow up and triage patients with HF. We will then discuss the current practices supported by medical societies, the role of pharmacotherapy and,…
View more
Author(s):
Carolyn Lam
Added:
8 years ago
Author(s):
Mark A Peterzan
,
Oliver J Rider
,
Lisa J Anderson
Added:
3 years ago
Heart failure (HF) can be defined haemodynamically as any abnormality of cardiac structure or function resulting in a failure to deliver oxygen at a rate adequate for tissue requirements, despite normal filling pressures – or only at the expense of increased filling pressures.1 Around half of patients with HF have reduced left ventricle ejection fraction (LVEF; EF <40 %) at rest (HF-REF).2
…
View more
De Novo HF Versus ADCHF
Author(s):
Wilson Matthew Raffaello
,
Joshua Henrina
,
Ian Huang
,
et al
Added:
3 years ago
Article
Author(s):
Frances M Russell
,
Matt Rutz
,
Peter S Pang
Added:
3 years ago
The emergency department (ED) plays a critical role in the initial diagnosis and management of acute heart failure (AHF),1,2 as nearly 80 % of all AHF admissions originate from the ER.3 However, patients do not present with a diagnosis; rather they present with a chief complaint reflecting signs and symptoms – most commonly breathlessness. Differentiating AHF from other causes of breathlessness…
View more
Author(s):
Andrew JS Coats
,
Louise G Shewan
Added:
3 years ago
What is Heart Failure?
Heart failure (HF) is a diagnosis made on clinical grounds, requiring at its simplest only a clinical history and physical examination findings, although, of course, certain investigations can help, especially imaging to assess left ventricular (LV) mechanical function. Unlike cancer, or even myocardial infarction (MI), there is no pathological or biochemical test that is…
View more
Author(s):
Syed Yaseen Naqvi
,
Ibrahim G Salama
,
Ayhan Yoruk
,
et al
Added:
3 years ago
Heart failure is a progressive and fatal disease that affects more than 23 million people worldwide, and will affect more than 8 million people in the USA by 2030.1,2 Despite major advancements in medical and device treatments for heart failure in recent decades, the incidence of heart failure continues to rise. This epidemic has a major impact on patient quality of life, while imposing heavy…
View more
Author(s):
Faiez Zannad
Added:
1 year ago
ESC Congress 22 — Dr Faiez Zannad (University of Lorraine, FR) joins us onsite at ESC to provide an update on the EMPEROR-Pooled trial, a pooled analysis of the EMPEROR-Preserved and EMPEROR-Reduced studies which aimed to evaluate the effects of empagliflozin on patients with heart failure.
9718 patients with heart failure were pooled into the study, where it was found that the use of…
View more